Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. develops treatments for complex rare diseases, with its lead program, nomlabofusp, focused on Friedreich’s ataxia. Nomlabofusp is a subcutaneously administered recombinant fusion protein designed to deliver frataxin to mitochondria, and company updates frequently address clinical data, frataxin measurement, FDA interactions and regulatory designations tied to that program.
Recurring LRMR news also covers operating and financial results, equity financing activity, corporate presentations and research publications related to its intracellular delivery platform. The company’s disclosures connect program development with capital needs, rare-disease regulatory pathways and the broader use of fusion proteins for diseases involving intracellular bioactive-compound deficiencies.
Larimar Therapeutics reported positive Phase 2 data for nomlabofusp in treating Friedreich's ataxia, with dose-dependent increases in frataxin levels. BLA submission expected in 2025, with FDA discussions ongoing. A financing round raised $161.8 million, extending cash runway to 2026. First patient dosed in OLE study with interim data due in Q4 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.